Mayne Pharma's Strategic Pivot: DistributeRx and the Menopause Tailwind
Fiscal 2026 results show a company reshaping its distribution model and betting on women's health, despite near-term EBITDA pressure.
MYX.AX · Earnings Call · 2026-08-26
DistributeRx: Reshaping the Pharmacy Value Chain
Mayne Pharma's fiscal 2026 results, reported on August 26, were a study in controlled turbulence. Revenue fell 6% to $383.7 million on a reported basis, but gross margin expanded 411 basis points to 64.7% — a direct consequence of mix shifts and disciplined pricing. Under the surface, the company is executing a rare strategic pivot: building a direct-to-patient pharmacy distribution business called DistributeRx, while doubling down on a women's health portfolio that is benefiting from a once-in-a-generation destigmatization of menopause. We unpack what changed and why it matters.
The launch of DistributeRx in March was the most consequential event of the year. The business is designed to remove the frictions of the U.S. pharmacy system — the handoffs, stage gates and opaque incentives that inflate costs and limit patient access. With the unit already operating at or above capacity, management announced a two-phase expansion targeting 2.5 million prescriptions per annum, backed by a $4 million capital equipment investment. “DistributeRx is a health care solutions business that partners with manufacturers to streamline prescription distribution and expand patient access, and it has exceeded expectations thus far.” — Aaron Gray, Chief Executive Officer · 2026-08-26 CEO Aaron Gray said on the call. And the pipeline is building: “We would expect to convert a significant percentage of those manufacturers in the near term.” — Aaron Gray, Chief Executive Officer · 2026-08-26 Gray added, referring to the seven additional partnerships in negotiation.
The U.S. health care system and consumer awareness are reaching a point being a participant in the U.S. health care system and a consumer where patients see diminishing and maybe little or no value in having insurance. In many cases, paying cash for a product is less costly to the patient than using their insurance, and that doesn't even include the cost of having the insurance.
Menopause: A Tailwind That's Hard to Overstate
Alongside the distribution pivot, Mayne's women's health segment is riding a powerful secular wave. The FDA's removal of the black box warning on BIJUVA in February has accelerated adoption, and the company estimates the menopause market will grow from $10-15 billion today to $15-25 billion by 2030 — a 60% increase. “Menopause is a – menopause has been an area that was, especially in the U.S., severely impacted by a study that was performed in 2002.” — Aaron Gray, Chief Executive Officer · 2026-08-26 Gray noted. Since then, usage of hormone replacement therapy collapsed from 27% of women to around 4-6%, leaving a massive headroom. BIJUVA prescriptions grew 26% and net sales 20% to $15 million; IMVEXXY grew 8% to $29.3 million. The company has increased its investment in a dedicated menopause sales force, and the hormone replacement therapy franchise is becoming a core growth engine. In Australia, NEXTSTELLIS got PBS listing in October and is generating record demand cycles, boosted by a $25 patient price and a differentiated profile.
Financial Discipline and Near-Term Frictions
The strategic moves come at a cost. Underlying underlying EBITDA fell 27% to $34.2 million, hit by the Cosette litigation, a $7.1 million short-term incentive charge, and $5.6 million of non-recurring managed care true-ups from the prior year. Management also took a $2.5 million adjustment for retention-related share-based expense, which they reclassified as one-off. Revenue declined 6% in Australian dollars, though this was almost entirely due to FX — on a constant currency basis, women's health grew 2%. Gross profit held flat at $248.1 million, aided by a dermatology mix shift toward higher-margin brands. The company's ability to expand gross margin while absorbing these costs is a testament to its pricing power and the early success of its Adelaide Apothecary e-pharmacy arm, which now carries 208 third-party products.
One persistent drag remains the product returns issue on ANNOVERA, which cost $11 million in revenue during the year. As Gray explained in a previous call: “So ANNOVERA returns come – returns come when we use the big 3, the channel, which is we call it the big 3, the large 3 wholesalers.” — Aaron Gray, Incoming CEO / Managing Director · 2026-02-22 The company is shifting to a more controlled specialty model to reduce this leakage. Meanwhile, the launch of a generic RHOFADE in July was already anticipated, and management flagged some insurance coverage loss for TWYNEO as a known headwind. “RHOFADE -- we acquired RHOFADE out of a bankruptcy proceeding. This was an extremely good acquisition.” — Aaron Gray, Incoming CEO / Managing Director · 2026-02-22 Gray reflected in a prior call, underscoring the team's ability to monetize assets.
The Path Forward
Management enters fiscal 2027 with clear objectives: grow the DistributeRx platform with more territories, products and partnerships; leverage the menopause momentum; and pursue capital-efficient acquisitions. Operating cash flow remained positive at $24.9 million, and the balance sheet shows $80 million in cash. The company expects one-off costs to normalise downward, which should allow the underlying earnings power to shine through. While the shares remain under pressure from the broader sector and the overhang of the Cosette litigation, the strategic repositioning — away from a traditional, channel-heavy model toward a direct, cash-pay, patient-centric one — is a genuine company-specific story. It's not a theme we see echoed widely in this quarter's earnings cycle, making Mayne's pivot a distinctive signal for investors.